Fig. 1 · Structure

Documents & Downloads

Evodiamine (Isoevodiamine)

Cat. No. A10376 CAS 518-17-2

TRP agonist

Evodiamine is a chemical extracted from the Tetradium family of plants. It acts primarily as a thermogenic and stimulant.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 > 200 μM Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay [PMID: 31880942]
HCT-116 IC50 > 200 μM Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay [PMID: 31880942]
MCF7 IC50 5.4 μM Antiproliferative activity against human MCF7 cells after 48 to 72 hrs by MTT assay 10.1039/C6MD00170J
MDA-MB-435 IC50 22.1 μM Antiproliferative activity against human MDA-MB-435 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay [PMID: 31880942]
MSTO-211H IC50 0.54 μM Antiproliferative activity against human MSTO-211H cells after 48 to 72 hrs by MTT assay 10.1039/C6MD00170J
NCI-H460 IC50 0.26 μM Antiproliferative activity against human H460 cells after 48 to 72 hrs by MTT assay 10.1039/C6MD00170J
NCI-H460 IC50 2.6 μM Cytotoxicity against human H460 cells after 72 hrs by MTT assay [PMID: 24103429]

Evodiamine (Isoevodiamine) Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Evodiamine (Isoevodiamine) from 3 published references. In vitro models include H1975; 253J. In vivo models include male WT C57BL/6 mice.

Evodiamine (Isoevodiamine) In Vitro Studies

Evodiamine treatment of H1975 cells for 72 h yielded an IC50 of 5.59 ± 0.88 μM in MTT cell viability assays. In 253J cells, Evodiamine yielded an IC50 of 1.90 ± 0.31 μM after 24 h, with viability assessed by MTT assay. In H1650 cells treated with Evodiamine for 72 h, MTT cell viability assays gave a reported value of 4.53 ± 1.46 μM. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Evodiamine and cell viability in H1975 cells

Cell-based study · H1975 [1]

H1975 cells were treated with Evodiamine for 72 h, and cell viability was measured by MTT assays. The IC50 was 5.59 ± 0.88 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cell viability was detected by MTT assaysIC50 5.59 ± 0.88 μM[1]

Literature-Reported Treatment Conditions

Exposure duration
72 h
Vehicle
dimethyl sulfoxide (DMSO)
Reported limits
Not stated in the sentences used: dose, route, control.
Methods and source locations

Compound reported in the paper: Evodiamine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and method reagents > Materials (S1); Results > Evodiamine can inhibit growth and induce apoptosis of NSCLC cells (S51, S54); Fig. 1 legend (S125)

cell viability was detected by MTT assays: cell viability was detected by MTT assays — Results > Evodiamine can inhibit growth and induce apoptosis of NSCLC cells (S54); Fig. 1 legend (S125)

Evodiamine and cell viability in 253J cells

Cell-based study · 253J [2]

253J cells were treated with Evodiamine for 24 h, and cell viability was assessed by MTT assay. The IC50 was 1.90 ± 0.31 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell viability was assessed by MTT assayIC50 1.90 ± 0.31 μM[2]

Literature-Reported Treatment Conditions

Exposure duration
24 h
Reported limits
Not stated in the sentences used: dose, route, vehicle.
Methods and source locations

Compound reported in the paper: Evodiamine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Evodiamine Induces Apoptosis in Human Bladder Cancer Cells (S2, S4); Figure 1. legend (S106)

Cell viability was assessed by MTT assay: Cell viability was assessed by MTT assay; comparator: control — Results > Evodiamine Induces Apoptosis in Human Bladder Cancer Cells (S4); Figure 1. legend (S106)

Evodiamine and cell viability in H1650 cells

Cell-based study · H1650 [1]

H1650 cells were treated with Evodiamine for 72 h, and cell viability was measured by MTT assays. The reported value was 4.53 ± 1.46 μM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cell viability was detected by MTT assaysIC50 4.53 ± 1.46 μM[1]

Literature-Reported Treatment Conditions

Exposure duration
72 h
Vehicle
dimethyl sulfoxide (DMSO)
Reported limits
Not stated in the sentences used: dose, route, control.
Methods and source locations

Compound reported in the paper: Evodiamine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and method reagents > Materials (S1); Results > Evodiamine can inhibit growth and induce apoptosis of NSCLC cells (S51, S54); Fig. 1 legend (S125)

cell viability was detected by MTT assays: cell viability was detected by MTT assays — Results > Evodiamine can inhibit growth and induce apoptosis of NSCLC cells (S54); Fig. 1 legend (S125)

Evodiamine (Isoevodiamine) In Vivo Studies

Male WT C57BL/6 mice received Evodiamine at 3 mg/kg by intraperitoneal injection, while control mice received the same amount of vehicle. Increased AMPK phosphorylation in aortas was observed as early as 1 h after injection. [3]

Evodiamine and aortic AMPK phosphorylation in mice

Animal study · Male WT C57BL/6 mice [3]

Male WT C57BL/6 mice received Evodiamine at 3 mg/kg by intraperitoneal injection, while control mice received the same amount of vehicle. Increased AMPK phosphorylation in aortas was observed as early as 1 h after injection.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
phosphorylated levels of AMPK in aortasReported result In WT mice, the increase in AMPK phosphorylation was induced as early as 1 h after injection[3]

Conditions shared by the study groups

Route
intraperitoneal (ip) injection
Treatment course
for the indicated times
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Evodiamine 3 mg/kgThe control mice received the same amount of vehicle.In WT mice, the increase in AMPK phosphorylation was induced as early as 1 h after injection[3]
Evodiamine 3 mg/kg
Model: Male WT C57BL/6 mice
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Evodiamine

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Mice (S16); Results > Role of AMPK in TRPV1 Ligand-Mediated eNOS Phosphorylation In Vivo (S113, S114, S117, S118, S121)

phosphorylated levels of AMPK in aortas: phosphorylated levels of AMPK in aortas; comparator: The control mice received the same amount of vehicle. — Results > Role of AMPK in TRPV1 Ligand-Mediated eNOS Phosphorylation In Vivo (S113, S114)

Evodiamine 3 mg/kg · Results > Role of AMPK in TRPV1 Ligand-Mediated eNOS Phosphorylation In Vivo (S114, S117)

Specifications

Manufacturer Adooq Bioscience
Actions Agonist
CAS Number 518-17-2
Applications TRP agonist
Formula C19H17N3O
Molecular Weight 303.4
Synonyms Isoevodiamine
SMILES
[H][C@@]1(N(C)C2=C3C=CC=C2)C4=C(C(C=CC=C5)=C5N4)CCN1C3=O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Insoluble
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Evodiamine (Isoevodiamine) Research References

  1. [1] Jiang ZB, Huang JM, Xie YJ, et al. Evodiamine suppresses non-small cell lung cancer by elevating CD8+ T cells and downregulating the MUC1-C/PD-L1 axis. J Exp Clin Cancer Res (2020). PMID: 33208183 DOI: 10.1186/s13046-020-01741-5 Source material
  2. [2] Zhang T, Qu S, Shi Q, et al. Evodiamine induces apoptosis and enhances TRAIL-induced apoptosis in human bladder cancer cells through mTOR/S6K1-mediated downregulation of Mcl-1. Int J Mol Sci (2014). PMID: 24566141 DOI: 10.3390/ijms15023154 Source material
  3. [3] Ching LC, Chen CY, Su KH, et al. Implication of AMP-activated protein kinase in transient receptor potential vanilloid type 1-mediated activation of endothelial nitric oxide synthase. Mol Med (2012). PMID: 22451268 DOI: 10.2119/molmed.2011.00461 Source material

Added to your cart

View Cart Checkout
Loading...